By joke Kujenya
HEADACHE DISORDERS rank among the most widespread neurological conditions, affecting an estimated 3.1 billion people worldwide, the World Health Organization (WHO) has confirmed.
These recurrent disorders, including migraine, tension-type headache, cluster headache and medication-overuse headache, impose substantial personal, social and economic burdens while remaining underdiagnosed and undertreated across the globe.
Characterised by repeated episodes of pain, headache disorders often disrupt work, school and daily life. Migraines, the third highest cause of neurological disability measured by age-standardised disability-adjusted life years (DALYs) in 2021, can last from four to 72 hours and are frequently accompanied by nausea, vomiting, and sensitivity to light and sound.
Tension-type headaches, typically described as a band-like pressure around the head, are more common in women and can persist for several hours to days.
Cluster headaches, though rare, present as intense, recurrent pain around one eye, often with tearing and nasal congestion, affecting six men for every woman.
Medication-overuse headache, resulting from frequent or excessive use of analgesics, represents the most common secondary headache disorder.
The prevalence of headache disorders spans all demographics, affecting people of all races, income levels and geographic regions. Globally, approximately 40% of the population experiences these conditions, with women disproportionately affected.
Onset can occur as early as age five, and headaches remain among the top three neurological conditions through age 80.
The disorders contribute to substantial personal suffering, impaired quality of life, and financial loss.
Individuals may endure repeated attacks alongside anxiety about future episodes, which can disrupt family and social life and reduce workplace productivity.
Studies indicate that people experiencing migraines face higher rates of anxiety and depression compared with those without the condition.
Migraine remains the most common primary headache disorder, typically beginning at puberty and affecting adults between 35 and 45 years of age.
Attacks are episodic but often lifelong and can include one-sided or pulsating head pain aggravated by routine physical activity.
Triggers vary, with alcohol, sleep disruption and certain foods commonly cited. Children may experience migraines differently, with shorter duration and more prominent abdominal symptoms.
Tension-type headaches begin in teenage years and are often linked to stress or musculoskeletal problems in the neck.
Episodic tension-type headaches, experienced fewer than 15 days per month, affect more than 70% of certain populations.
Chronic forms, however, are unremitting and more disabling. Cluster headaches are brief but excruciating, recurring multiple times daily, with accompanying autonomic symptoms such as drooping eyelids and nasal congestion.
This disorder is uncommon, affecting fewer than 1 in 1,000 adults, with the majority of cases beginning in the 20s or later.
Medication-overuse headache arises from chronic excessive use of pain-relief medication. Occurring more days than not, it is persistent, oppressive, and often worst on awakening.
Women are more frequently affected, and up to 5% of certain populations may experience the disorder.
The social and economic consequences of headache disorders are significant. Impaired productivity, reduced employment prospects, and social strain are common.
Individuals often continue working despite debilitating symptoms, compounding stress and economic loss for both themselves and society.
Despite these effects, many sufferers do not receive adequate diagnosis or treatment.
Barriers include limited knowledge among healthcare providers, poor public awareness, restricted access to medications such as sumatriptan for migraines, and underrecognition by governments focused on constraining healthcare costs.
WHO identifies proper diagnosis, timely treatment, and education as critical to managing headache disorders.
Effective care involves training healthcare professionals, accurate diagnosis, and patient education.
Available interventions include analgesics, anti-emetics, specific anti-migraine medications, and prophylactic therapies.
Simple lifestyle modifications, such as maintaining hydration, consistent sleep schedules, avoiding alcohol, healthy diet, exercise, and use of headache diaries to track triggers, can provide substantial relief.
Early intervention is particularly important in migraine management, with analgesics recommended at the onset of symptoms or aura.
WHO has taken steps to strengthen global response to headache disorders. The Atlas of Headache Disorders, published in 2011, mapped the burden and available resources for headache care.
In May 2022, the World Health Assembly endorsed the Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022–2031, which aims to close gaps in diagnosis, treatment and care for neurological disorders including headache.
The plan focuses on enhancing governance, raising policy prioritisation, promoting timely access to care, implementing prevention strategies, supporting research, and strengthening health information systems.
Access to essential medicines is recognised as a cornerstone of treatment.
WHO’s 24th Model List of Essential Medicines specifies safe, effective, and cost-efficient drugs for headache disorders that should be available within basic healthcare systems.
Despite the widespread prevalence and impact of headache disorders, WHO notes that under-recognition remains a global challenge.
Many individuals self-treat, unaware that effective therapies exist. Lack of public awareness perpetuates the perception of headaches as minor or non-serious conditions.
Governments and healthcare systems face the task of recognising the broader societal and economic burdens, as the cost of treatment is minimal relative to the potential savings from reduced absenteeism and improved productivity.
WHO says it continues to collaborate with nongovernmental organisations and healthcare partners to improve awareness, diagnosis, and treatment access worldwide.
Also, the organisation emphasises that with appropriate care, education, and lifestyle measures, individuals can significantly reduce the impact of headache disorders and improve their quality of life.
